chromosome 19 open reading frame 84Genealiases: []
Q-omics provides the consensus-scored C19orf84 profile across patient tissues and cancer cell-line models. C19orf84 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, C19orf84 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, C19orf84 RNA expression shows 12,197 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, HNSC, and THYM as cancer lineages where C19orf84 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C19orf84 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C19orf84 survival associations across molecular data types. C19orf84 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C19orf84 RNA expression–survival associations across cancer types. High C19orf84 expression shows unfavorable associations in BLCA, KIRC, LGG, LAML and LIHC, but favorable associations in CESC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify CESC as the clearest survival context for C19orf84 RNA expression.
This table summarizes C19orf84 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C19orf84. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C19orf84 shows higher tumor expression in HNSC, KIRC, KIRP, BRCA, STAD and LUSC. The HNSC box plot shows higher C19orf84 RNA expression in tumor versus normal tissue (log2 FC = +1.011, t-test p < 0.001).
This table shows molecular features associated with C19orf84 in patient tissues and cancer cell lines. In patient samples, C19orf84 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, C19orf84 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
